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Background: The Mediterranean diet (MD) has been proposed as a means for cancer prevention, but little evidence has been
accrued regarding its potential to prevent pancreatic cancer. We investigated the association between the adherence to the MD
and pancreatic cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort.
Methods: Over half a million participants from 10 European countries were followed up for over 11 years, after which 865 newly
diagnosed exocrine pancreatic cancer cases were identified. Adherence to the MD was estimated through an adapted score without the
alcohol component (arMED) to discount alcohol-related harmful effects. Cox proportional hazards regression models, stratified by age,
sex and centre, and adjusted for energy intake, body mass index, smoking status, alcohol intake and diabetes status at recruitment, were
used to estimate hazard ratios (HRs) associated with pancreatic cancer and their corresponding 95% confidence intervals (CIs).
Results: Adherence to the arMED score was not associated with risk of pancreatic cancer (HR high vs low adherence¼ 0.99; 95%
CI: 0.77–1.26, and HR per increments of two units in adherence to arMED¼ 1.00; 95% CI: 0.94–1.06). There was no convincing
evidence for heterogeneity by smoking status, body mass index, diabetes or European region. There was also no evidence of
significant associations in analyses involving microscopically confirmed cases, plausible reporters of energy intake or other
definitions of the MD pattern.
Conclusions: A high adherence to the MD is not associated with pancreatic cancer risk in the EPIC study.
Pancreatic cancer, of which pancreatic ductal adenocarcinoma is
the most common type, is estimated to become the second leading
cause of cancer-related death by 2030 in the United States (Rahib
et al, 2014). A trend of increasing mortality rates for pancreatic
cancer is also foreseen in Europe (Malvezzi et al, 2015; Ferlay et al,
2016). The past decade has witnessed little therapeutic progress for
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this disease and obstacles to primary prevention persist on grounds
of insufficient knowledge of the causative factors. In fact, only few
risk factors of pancreatic cancer are well established, namely
smoking, non-O blood group, obesity, diabetes mellitus, heavy
alcohol drinking and chronic pancreatitis (Maisonneuve and
Lowenfels, 2015). The identification of additional risk factors is a
challenge due to the complex and multi-factorial aetiology of
pancreatic cancer. Dietary factors, which could be potentially
modifiable, have not been consistently linked to pancreatic cancer
(AICR/WCRF, 2012).
Results from numerous epidemiological studies support the
hypothesis that the Mediterranean diet (MD) is associated with a
reduced cancer risk (Couto et al, 2011; Benetou et al, 2008;
Schwingshackl and Hoffmann, 2014), as for example concerns breast
(Buckland et al, 2013), colorectal (Bamia et al, 2013) and gastric cancers
(Buckland et al, 2010). The underlying mechanisms by which the MD
may exert this cancer-preventive effect are based on the inhibition of
inflammatory, mutagenic and proliferative pathways in the carcinogenic
process, and have been attributed to the synergistic interplay of various
nutritional components, for example, omega 6 and omega 3 fatty acids,
fibre, antioxidants and polyphenols, provided by fruits, vegetables,
legumes, olive oil and wine (Giacosa et al, 2013). There is,
however, limited and inconsistent data on the association between a
priori-defined scores of adherence to the MD and pancreatic cancer
risk, with an Italian case–control study of nearly 700 pancreatic cancer
cases reporting a significant inverse association (Bosetti et al, 2013a),
and two prospective studies, one conducted in the United
States (n¼ 1057 cases) and another one in Sweden (n¼ 92 cases),
reporting conflicting results (Jiao et al, 2009; Tognon et al, 2012). The
null results from the US study could be attributed to an overall lower
adherence to the MD compared with European populations, whereas
the sample size of the Swedish study undermines the reliability of a true
inverse association between the MD and pancreatic cancer risk. Studies
on a posteriori-defined MD patterns and their association with
pancreatic cancer risk have also reported contradictory results
(Michaud et al, 2005; Nkondjock et al, 2005; Inoue-Choi et al, 2011;
Chan et al, 2013; Bosetti et al, 2013b). Therefore, it remains
inconclusive whether an association between the MD and pancreatic
cancer risk exists.
Despite the absence of a consistent pattern of association, a possible
link between the MD and pancreatic cancer risk is supported by the fact
that some dietary components of the MD have been associated
individually with a reduced risk (e.g., fruits and vegetables) or increased
risk (e.g., meat) of pancreatic cancer (Wu et al, 2016; Rohrmann et al,
2013). Further support for this association comes from the well-known
MD and diabetes mellitus association. A high adherence to the MD as
compared with a low adherence leads to a decreasing risk of diabetes
mellitus (InterAct Consortium et al, 2011; Koloverou et al, 2014), which
could subsequently reduce the risk of pancreatic cancer owing to the
causal link between both diseases. Thus, the MD could have a potential
role in reducing pancreatic cancer risk through diabetes as a mediating
factor in this relationship, or by being a common preventive factor of
both diabetes and pancreatic cancer.
Our aim was to prospectively investigate the association
between adherence to an a priori-defined MD index and pan-
creatic cancer risk. To this end we used a large European study
population, featuring a wide range of variability in adherence to
the MD across a North–South gradient, which also included
Mediterranean populations.
MATERIALS AND METHODS
Study population. European Prospective Investigation into
Cancer and Nutrition is a multicenter prospective cohort study
conducted in 23 centres in 10 European countries (Italy, France,
Denmark, Germany, Greece, Spain, Norway, Sweden, UK and The
Netherlands). Over half a million participants (30% men) were
recruited in the 1990s from the general population, except in some
centres where other target populations were approached: breast
cancer screening participants in Florence (Italy) and Utrecht (The
Netherlands), mostly blood donors in Italy and Spain, vegetarian
and health-conscious volunteers in Oxford (UK), and female
members of the health insurance scheme for state school employ-
ees in France. European Prospective Investigation into Cancer and
Nutrition was approved by the Internal Review Board of the
International Agency for Research on Cancer, as well as by local
institutions of the participating centres. All participants provided
written informed consent. Methods of recruitment have been
described in detail elsewhere (Riboli and Kaaks, 1997; Riboli et al,
2002).
We excluded a total of 23 785 participants with prevalent cancer
at baseline other than non-melanoma skin cancer, 4383 partici-
pants with missing or incomplete information on follow-up, 6253
participants with incomplete dietary or non-dietary data and 9600
participants with a ratio for energy intake vs energy expenditure in
the top or bottom 1%. The final study sample comprised 477 309
participants (29.8% men).
Pancreatic cancer cases ascertainment. Record linkage with
population-based cancer registries and national mortality registries
was performed to identify incident cancer cases and to assess the
vital status of the participants. Complete follow-up data were
obtained between 2004 and 2008 depending on the EPIC centre.
Active follow-up was carried out in Germany (up to 2008 for
Potsdam and mid-2010 for Heidelberg), Greece (up to 2009) and
France (up to 2006) by reviewing cancer, pathology and health
insurance records of each participant, and also by directly
contacting their next-of-kin. The mean duration of follow-up
was 11.3 years.
Incident pancreatic cancer cases were defined as exocrine
adenocarcinomas (International Classification of Diseases for
Oncology, Third Edition (ICD-O-3), codes C25.0–C25.3, C25.7–
C25.9). Endocrine tumours (n¼ 40), secondary tumours (n¼ 67)
and tumours of uncertain, benign or metastatic behaviour (n¼ 3)
were all censored at the date of their diagnosis. We ended up
with 865 pancreatic cancer cases, of which 608 cases (70.3%)
were microscopically confirmed, based on histology of the primary
tumour, histology of the metastasis, cytology or autopsy.
Assessment of diet and adherence to the MD. Participants were
asked about their habitual diet over the previous year using
country-specific validated dietary questionnaires (Riboli et al,
2002), namely: quantitative food frequency questionnaires in
Germany, Greece, Northern Italy and the Netherlands, diet history
questionnaires in Spain, France and Ragusa (Italy), and semi-
quantitative food frequency questionnaires in Denmark, Naples
(Italy), Norway, the UK (combined with a 7-day record) and Umeå
(Sweden). In Malmo¨ (Sweden), a quantitative food frequency
questionnaire and a 7-day food record with menu book to estimate
portion sizes were used. The EPIC nutrient database was used to
estimate nutrient and total energy intake from the dietary
questionnaires (Slimani et al, 2007).
The relative Mediterranean diet score (rMED), as previously
applied in other EPIC studies (Buckland et al, 2010, 2013) and similar
in concept to the original MD score (Trichopoulou et al, 2003), was
used to estimate level of conformity to the MD. It is an 18-point scale
that incorporates nine selected components of the MD. Each
component was calculated as a function of energy density (g per
1000 kcal per day), using the nutrient density model (Willet el al,
1997), and then divided into country-specific tertiles of intakes (except
for olive oil). For the six components presumed to fit the MD; fruits
(including nuts and seeds), vegetables (excluding potatoes), legumes,
fish (including seafood), olive oil and cereals (white and nonwhite), a
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score of 0–2 points was assigned to the first (0 points), second
(1 point) and third (2 points) tertile of intake, respectively. The
scoring scheme for olive oil consisted of assigning 0 points to non-
consumers, 1 point for participants below the median of intake and 2
points for levels of intake equal or above this median. For the 2
components presumed not to fit MD, meat (including meat products)
and dairy products, the scoring was reversed (first, second and third
tertile: 2, 1 and 0 points, respectively). Because alcohol consumption
has been potentially associated with pancreatic cancer (Maisonneuve
and Lowenfels, 2015), the alcohol component (the ninth component)
was removed from the score and the non-alcohol MD score (arMED)
was used instead (Buckland et al, 2013). Thus, the range of the
arMED score contained eight components and the point scale ranks
from 0 to 16, whereby 0 represents the lowest adherence to the MD
pattern and 16 the highest adherence. The arMED score was further
classified into low (0–5 points), medium (6–9 points) or high (10–16
points) adherence levels based on the previously published cutoff
points (Buckland et al, 2013).
Lifestyle data. Standardised questionnaires were used to collect
lifestyle data at recruitment including self-reported diabetes status,
history of smoking and alcohol consumption, physical activity and
socio-economic status. Diagnosis of diabetes of about half of
all self-reported cases was confirmed through linkage to diabetes
mellitus registries, patient records or using other procedures
(No¨thlings et al, 2011). Height and weight were measured in all
EPIC centres except in Norway, France and in a subgroup of the
Oxford cohort where these data were self-reported. Anthropo-
metric measurements also included waist circumference, except in
Norway, in Umeå and in Oxford where only self-reported data
were collected (Riboli et al, 2002). Measurements were corrected
for differences in clothing and self-reported data of the aforemen-
tioned centres were corrected using prediction equations based on
a fraction of real measurements (Haftenberger et al, 2002).
Statistical analysis. Cox proportional hazards regression models
were used to estimate hazard ratios (HRs) and 95% confidence
intervals (CIs) for adherence to the arMED score associated with
pancreatic cancer risk. Regression models were stratified by age
at recruitment in 1-year categories, sex and centre to control for
between-centre differences in the dietary assessment methods used
at recruitment and differences in follow-up procedures. Time at
entry was age at recruitment, and time at exit was age at first
pancreatic cancer diagnosis for cases and age at censoring for non-
cases (death, loss to follow-up or end of the follow-up, whichever
came first). The proportional hazard assumption was satisfied in all
models as indicated by the plots of Schoenfeld residuals on
functions of time (Schoenfeld, 1982).
Adherence to the arMED was modelled as a categorical variable
by dividing the score into low, medium and high levels of
adherence. The low adherence category was considered as the
referent group. The trend of association across levels of adherence
was evaluated by using a linear variable of the medians of the score
in each stratum.
Adherence to the arMED was also modelled on a continuous
scale to estimate risks associated per increments of two units in the
adherence. Restricted cubic splines functions in models of three
and four knots on the distribution of the arMED score, to evaluate
the shape of the dose–response relationship between the arMED
and pancreatic cancer risk (Heinzl and Kaider, 1997), suggested a
linear relationship.
Covariates considered a priori as factors known or suspected to
be associated with pancreatic cancer risk and the MD were tested
for confounding by comparing models with and without each
variable. Those variables that changed estimates by more than 10%
were retained in the regression model. Physical activity and
educational level did not comply with these criteria. Risk estimates
for models with waist circumference or body mass index (BMI) did
not substantially differ. The association of adherence to the arMED
score with pancreatic cancer risk was examined in crude models
(stratified by age, sex and centre), and in multivariate models
(additionally adjusted for energy intake, BMI, smoking status,
alcohol intake and diabetes status).
The modifying effect of sex, BMI (normal, overweight and
obese, according to WHO criteria), waist circumference (normal/
moderate and large, according to National Cholesterol Education
Program (NCEP) Expert Panel on Detection, Evaluation, and
Treatment of High Blood Cholesterol in Adults (Adult Treatment
Panel III), 2002), physical activity (active and non-active) to
elucidate further the potential effect-measure modification of
overweight and obesity, smoking status (never, former and current
smoker), median age at recruitment (o60 and X60 years) and
alcohol consumption (abstainers, moderate drinkers and drinkers,
equivalent to 0 g/day, p12 g/day or 412 g/day alcohol use,
respectively) was evaluated through stratified analyses and the
likelihood ratio test statistic in regression models with and without
multiplicative interaction terms between these variables and the
arMED score. In addition, we considered the influence of smoking
duration and intensity on the arMED and pancreatic cancer risk
association in current and former smokers. Heterogeneity by
country and region (Southern, Central and Northern Europe) was
also assessed by introducing an interaction term between
countries/regions and the arMED score in the model.
The possible mediating effect of diabetes mellitus on this
association was further evaluated in two different scenarios using
mediation analysis (Tingley et al, 2014): (i) a direct effect of the
arMED score on pancreatic cancer risk; and (ii) an indirect effect
with diabetes mellitus as an intermediate in the causal pathway.
A logistic regression model of the arMED score on diabetes
status at baseline, followed by a hazard model to the onset of
pancreatic cancer including arMED and the same covariates as
well as the mediator variable (diabetes status) were fitted to
estimate the average direct and the average causal mediation effect
of diabetes.
Sensitivity analyses were performed by the exclusion of cases
diagnosed within the first 2 years of follow-up (88 cases) to
evaluate the influence of early effects of subclinical disease on the
associations as well as those occurred within the first 5 years of
follow-up (258 cases) to account for another time point of disease
progression. We also excluded (i.e., censored) non-microscopically
confirmed cases (257 cases) to minimise possible misclassification
of tumours. Analyses were further restricted to 523 confirmed
cases belonging to the pancreatic ductal adenocarcinoma histolo-
gical subtype. Hazard ratios of pancreatic cancer associated with
adherence to the arMED score were compared with the score
including alcohol as an additional component, that is, the original
rMED score (Buckland et al, 2010). Alcohol was scored
dichotomously assigning two for moderate consumption (sex-
specific cutoff points: 5–25 g per day for women and 10–50 g per
day for men) and 0 for intakes outside this range. Other sensitivity
analyses included the comparison of HRs estimated using cohort-
wide tertiles, the Mediterranean diet scale (MDS; Trichopoulou
et al, 2003) and the Mediterranean dietary pattern MDP scores
(Sa´nchez-Villegas et al, 2006). Analyses excluding misreporters
of energy intake, as defined by Goldberg (under-repoters if ratio
of energy intake:basal metabolic rate -EI:BMR o1.14 and
over-reporters if EI:BMR 42.1), were also conducted (Goldberg
et al, 1991). In addition, each dietary component of the MD
score was subtracted one at a time from the arMED score to
investigate whether the removed component changed the risk
estimates with respect to the regression models of the complete
arMED score.
Statistical software used for the data analysis were Stata 12.0
(College Station, TX, USA: Stata Corp LP, 2005) and R 3.2.1.
Statistical significance was based on two-sided P values o0.05.
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RESULTS
The arMED score ranged between 4 and 11.3 points (mean score:
7.81±2.63). Mean overall adherence to the arMED score was
higher in southern European countries than in northern European
countries, except in the UK (possibly driven by the vegetarian and
health-conscious participants of the Oxford subcohort)
(Supplementary Table 1). According to the participants’ demo-
graphic and lifestyle characteristics, higher levels of adherence to
the arMED score were more frequent among those who were
younger, less educated, non-smokers, physically inactive or obese.
Participants with self-reported diabetes mellitus at baseline also
showed a higher adherence level to this dietary pattern probably as
a result of adopting healthier dietary habits to manage their
disease. Intakes of nutrient antioxidants, fibre, plant-based food
and olive oil were higher in the high adherence group, while that of
dairy products and meats was lowest (Table 1).
Table 2 shows HR estimates of adherence to the arMED score
associated with pancreatic cancer risk, overall and by subgroups.
Compared with a low level of adherence to the arMED score, a
higher adherence was not associated with risk of pancreatic cancer,
either in the minimally adjusted (HR¼ 0.88; 95% CI: 0.69–1.12;
p-trend¼ 0.24), or multivariate-adjusted models (HR¼ 0.99; 95%
CI: 0.77–1.26; p-trend¼ 0.95). HRs associated to increments of two
units in the adherence to the arMED score did also not reach
statistical significance (HR¼ 1.00; 95% CI: 0.94–1.06).
No indication for effect modification by BMI, age, smoking status,
sex, physical activity, alcohol status and abdominal obesity was
apparent (P-value for interaction¼ 0.43, 0.59, 0.56, 0.90, 0.46, 0.20
and 0.76, respectively). There was also no evidence for interaction by
diabetes status (P-value¼ 0.11). Hazard ratios for pancreatic cancer
per two units increment in arMED in non-diabetics tended to be
inversely associated with pancreatic cancer risk in crude models
(HR¼ 0.97; 95% CI: 0.94–1.00), but not after adjusting for smoking in
the multivariate-adjusted model (HR¼ 0.98; 95% CI: 0.91–1.04). No
such inverse pattern of association was observed in the subset of
diabetics, although a relatively small number of pancreatic cancer
cases (n¼ 55) were available for this analysis (data not shown).
Results of the mediation analysis also did not support a mediating
effect of diabetes on this association (average causal mediation effect
P-value¼ 0.90, average direct effect P-value¼ 0.02).
Stratified analyses by country or European region did not reveal
statistically significant heterogeneity between strata for the
association between adherence to the arMED score with pancreatic
cancer risk (P-value¼ 0.62 and 0.11, respectively). A borderline
inverse association in the southern European cohort was observed,
yet without reaching statistical significance (HR per two unit
increment in arMED¼ 0.88; 95% CI: 0.76–1.03, P-value¼ 0.07).
Results of the sensitivity analyses are shown in Table 3 and
Supplementary Table 2. Hazard ratios remained virtually the
same in analyses restricted to microscopically confirmed cases
or to participants with a follow-up longer than 2 or 5 years.
No differences in the associations were further observed for
Table 1. Baseline characteristics of the EPIC cohort (n¼477309) according to adherence to the arMED score
arMED score in men arMED score in women
Characteristics Low (0–5) Medium (6–9) High (10–16) Low (0–5) Medium (6–9) High (10–16)
Adherence arMED (mean±s.d.) 3.85 (1.14) 7.35 (1.11) 11.37 (1.32) 4.14 (1.01) 7.54 (1.10) 11.28 (1.28)
Age, years (mean±s.d.) 52.3±9.9 52.6±10.0 51.2±10.6 51.4±9.7 51.2±9.3 49.8±10.6
Education Xsecondary school, n (%) 32 690 (66.1) 39 000 (66.6) 18 781 (54.9) 41 981 (69.3) 119 520 (71.0) 65 328 (61.6)
Weight, kg (mean±s.d.) 82.0±12.4 80.7±11.8 79.4±11.6 67.2±12.3 65.5±11.5 65.0±11.4
BMI, kg m2 (mean±s.d.) 26.3±3.6 26.4±3.6 27.0±3.8 25.1±4.4 24.7±4.2 25.2±4.6
Obese (X30 kg m2), n (%) 6926 (14.0) 8278 (14.1) 6596 (19.3) 7780 (12.9) 18 547 (11.0) 15 912 (15.0)
Waist circumference, cm (mean±s.d.) 95.0±10.4 94.0±10.0 95.2±10.2 81.0±11.4 79.6±11.0 80.3±11.9
X102 cm in men or X88 cm in women, n (%) 9832 (19.9) 11 232 (19.2) 8601 (25.1) 11 022 (18.2) 23 151 (13.8) 21 266 (20.1)
Physical activity 4moderate active, n (%) 24 329 (49.2) 28 274 (48.3) 16 315 (47.7) 24 169 (39.9) 59 685 (35.4) 34 380 (32.4)
Current smoker, n (%) 16 269 (32.9) 15 779 (26.9) 9758 (28.5) 17 069 (28.2) 32 311 (19.2) 15 903 (15.0)
Alcohol intake, median g (IQR) 12.1 (4.1–29.2) 13.8 (4.8–30.7) 13.04 (3.4–29.8) 3.8 (0.8–11.4) 3.9 (0.8–11.6) 2.8 (0.4–10.2)
Heavy intake (X96g per day in men orX60g
per day in women), n (%)
3623 (7.3) 3853 (6.6) 1887 (5.5) 637 (1.1) 1178 (0.7) 361 (0.3)
Dietary intake
Total energy intake, kcal (mean±s.d.) 2470±665 2391±657 2356±660 1956±533 1929±543 1921±539
Carbohydrate, g (mean±s.d.) 261.4±80.6 259.5±82.4 250.7±79.9 211.0±65.6 213.8±66.6 219.7±69.1
Fat, g (mean±s.d.) 98.7±33.0 91.0±31.4 91.8±33.2 79.7±26.7 75.7±26.9 74.4±26.8
Saturated fat, g (mean±s.d.) 41.2±14.8 34.6±13.0 28.2±11.3 33.9±12.4 30.1±11.8 25.7±10.6
Vitamin C, mg (mean±s.d.) 96.5±52.1 121.9±67.3 158.5±88.6 100.7±54.7 128.9±65.5 154.5±73.8
Vitamin E, mg (mean±s.d.) 11.7±6.0 13.3±6.4 14.7±6.7 10.8±5.2 11.8±5.4 12.6±5.4
Beta-carotene, mg (mean±s.d.) 2327.3±1980.6 3080.5±2589.8 4062.6±3284.8 2917.0±2086.0 3735.4±2668.0 4660.2±3591.7
Folate, mg (mean±s.d.) 285.7±90.4 313.6±109.1 376.5±139.9 254.2±87.2 293.2±109.9 348.6±37.6
Fibre, g (mean±s.d.) 21.5±7.3 24.5±8.0 28.0±8.9 18.5±5.9 21.6±6.5 25.1±8.0
Meat and meat products, g (mean±s.d.) 148.6±69.0 120.9±65.4 96.6±65.7 109.0±49.8 92.0±50.6 67.8±48.3
Dairy products, g (mean±s.d.) 450.8±321.0 311.0±225.3 214.9±164.6 434.4±263.4 329.9±211.2 245.7±172.0
Fruit, nuts and vegetables, g (mean±s.d.) 234.8±131.0 387.6±218.9 693.4±323.5 278.3±151.4 431.4±223.8 637.4±282.7
Cereals, g (mean±s.d.) 214.0±95.6 269.7±135.6 295.0±135.8 162.8±71.0 197.5±93.5 235.5±109.7
Legumes, g (mean±s.d.) 4.4±10.6 14.3±26.5 35.9±36.6 4.2±9.6 10.3±17.2 25.3±25.8
Fish, g (mean±s.d.) 27.5±25.6 36.5± 32.0 48.6±43.9 24.6±28.1 38.7±37.5 43.4±37.4
Olive oil, g (mean±s.d.) 0.4±2.3 7.0±14.0 26.1±23.5 0.5±2.4 3.6±9.2 12.6±17.1
Diabetes, yes (self-reported), n (%) 1309 (2.7) 2219 (3.8) 1572 (4.6) 1090 (1.8) 3440 (2.0) 2902 (2.7)
All dietary intakes are estimated from the food frequency questionnaire and not energy-adjusted. Missing data on educational level for 1260 men and 4964 women; physical activity for 3075
men and 38 956 women; waist circumference for 12 043 men and 94 998 women; smoking status for 1959 men and 7774 women; diabetes status at recruitment for 3096 men and 13 745 women.
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Table 2. Hazard ratios (95% confidence intervals) of pancreatic cancer by country-specific levels of adherence to the arMED score
in the EPIC cohort (n¼477309)
arMED score Per two unit increment in arMED score
Low (0–5) HR
(95% CI)
Medium (6–9) HR
(95% CI)
High (10–16) HR
(95% CI)
P-value for trend HR (95% CI)
All (n¼865 cases)
Cases/person-years 277/1 245 196 402/2 483 735 186/1 534 067
Crude HR (95% CI) 1.00 0.94 (0.80–1.11) 0.88 (0.69–1.12) 0.24 0.98 (0.95–1.01)
Multivariate HR (95% CI) 1.00 1.01 (0.85–1.19) 0.99 (0.77–1.26) 0.95 1.00 (0.94–1.06)
Men (n¼396 cases) P-value for interaction: 0.90
Cases/person-years 165/565 143 160/649 987 71/376 379
Crude HR (95% CI) 1.00 0.92 (0.73–1.16) 0.88 (0.59–1.30) 0.45 0.97 (0.88–1.06)
Multivariate HR (95% CI) 1.00 0.99 (0.78–1.25) 1.00 (0.68–1.49) 0.99 1.01 (0.92–1.11)
Women (n¼469 cases)
Cases/person-years 112/680 053 242/1 833 748 115/1 157 688
Crude HR (95% CI) 1.00 0.96 (0.76–1.21) 0.89 (0.65–1.22) 0.46 0.96 (0.88–1.04)
Multivariate HR (95% CI) 1.00 1.03 (0.82–1.31) 0.99 (0.72–1.37) 0.98 0.99 (0.91–1.08)
Ageo60 years (n¼486 cases) P-value for interaction: 0.59
Cases/person-years 168/965 742 225/1 970 708 93/1 249 488
Crude HR (95% CI) 1.00 0.88 (0.71–1.09) 0.71 (0.51–0.98) 0.04 0.94 (0.87–1.03)
Multivariate HR (95% CI) 1.00 0.95 (0.76–1.18) 0.80 (0.58–1.12) 0.23 0.98 (0.90–1.07)
Age X60 years (n¼379 cases)
Cases/person-years 109/279 454 177/513 027 93/284 579
Crude HR (95% CI) 1.00 1.03 (0.80–1.33) 1.16 (0.80–1.67) 0.46 0.99 (0.89–1.08)
Multivariate HR (95% CI) 1.00 1.10 (0.85–1.41) 1.30 (0.89–1.87) 0.18 1.02 (0.92–1.12)
Never smoker (n¼336 cases) P-value for interaction: 0.56
Cases/person-years 81/518 518 169/1 229 294 86/847 954
Crude HR (95% CI) 1.00 1.02 (0.77–1.36) 0.91 (0.62–1.34) 0.65 0.98 (0.88–1.08)
Multivariate HR (95% CI) 1.00 1.03 (0.77–1.37) 0.92 (0.63–1.37) 0.71 0.98 (0.89–1.09)
Former smoker (n¼239 cases)
Cases/person-years 68/340 265 115/681 518 56/376 769
Crude HR (95% CI) 1.00 1.13 (0.83–1.55) 1.35 (0.87–2.12) 0.19 1.03 (0.92–1.16)
Multivariate HR (95% CI) 1.00 1.15 (0.83–1.57) 1.42 (0.91–2.22) 0.13 1.05 (0.93–1.18)
Smoker (n¼247 cases)
Cases/person-years 126/371 157 109/519 272 40/278 996
Crude HR (95% CI) 1.00 0.84 (0.64–1.12) 0.66 (0.40–1.08) 0.09 0.94 (0.84–1.05)
Multivariate HR (95% CI) 1.00 0.86 (0.65–1.14) 0.67 (0.41–1.11) 0.11 0.95 (0.85–1.06)
Non-diabetics (n¼776 cases) P-value for interaction: 0.11
Cases/person-years 259/1 174 297 355/2 321 163 162/1 448 174
Crude HR (95% CI) 1.00 0.89 (0.75–1.05) 0.81 (0.63–1.05) 0.09 0.97 (0.94–1.00)
Multivariate HR (95% CI) 1.00 0.95 (0.80–1.13) 0.91 (0.70–1.19) 0.48 0.98 (0.91–1.04)
Obese (n¼144 cases)a P-value for interaction: 0.43
Cases/person-years 45/161 481 65/290 699 34/245 613
Crude HR (95% CI) 1.00 1.03 (0.67–1.57) 0.53 (0.28–1.03) 0.11 0.90 (0.77–1.05)
Multivariate HR (95% CI) 1.00 1.06 (0.69–1.64) 0.56 (0.29–1.08) 0.14 0.91 (0.78–1.08)
Overweight (n¼363 cases)b
Cases/person-years 115/478 180 164/ 837 232 84/527 638
Crude HR (95% CI) 1.00 0.99 (0.77–1.28) 1.05 (0.72–1.53) 0.83 0.99 (0.90–1.09)
Multivariate HR (95% CI) 1.00 1.08 (0.83–1.40) 1.19 (0.81–1.73) 0.38 1.03 (0.94–1.14)
Normal weight (n¼358 cases)b
Cases/person-years 117/605 535 173/1 355 804 68/760 817
Crude HR (95% CI) 1.00 0.90 (0.70–1.16) 0.92 (0.64–1.32) 0.56 0.98 (0.94–1.03)
Multivariate HR (95% CI) 1.00 0.97 (0.75–1.25) 1.02 (0.70–1.47) 0.97 1.00 (0.90–1.10)
Physically active (n¼173 cases) P-value for interaction: 0.46
Cases/person-years 117/555 538 157/980 914 49/560 756
Crude HR (95% CI) 1.00 1.04 (0.80–1.34) 0.81 (0.53–1.24) 0.53 0.98 (0.89–1.09)
Multivariate HR (95% CI) 1.00 1.09 (0.84–1.41) 0.89 (0.58–1.36) 0.86 1.01 (0.91–1.12)
Non-physically active (n¼505 cases)
Cases/person-years 151/596 061 220/1 231 169 134/908 833
Crude HR (95% CI) 1.00 0.88 (0.70–1.10) 0.92 (0.67–1.26) 0.58 0.97 (0.89–1.05)
Multivariate HR (95% CI) 1.00 0.94 (0.75–1.18) 1.04 (0.75–1.43) 0.89 1.00 (0.92–1.09)
Non-drinkers (n¼109 cases)a P-value for interaction: 0.20
Cases/person-years 34/127 697 45/300 841 30/277 857
Crude HR (95% CI) 1.00 0.78 (0.48–1.27) 0.68 (0.33–1.39) 0.26 0.92 (0.77–1.11)
Multivariate HR (95% CI) 1.00 0.84 (0.51–1.39) 0.78 (0.38–1.63) 0.49 0.97 (0.80–1.16)
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pancreatic ductal adenocarcinoma tumours. The distribution of
participants by the arMED score either defined as country-specific
or cohort-wide tertiles was similar (23.1%, 46.7%, 29.4% and
24.2%, 45.3%, 30.5%, respectively) and HR estimates did not
appreciably change when cohort-wide tertiles of the arMED score
were used as the exposure of interest variable. We did also not
observe any variations in risk estimates when considering
adherence to the rMED score, that is, the score including
alcohol, instead. The same was true for the other MD scores (MDS
and MDP), with or without the contribution of alcohol
to the scores. Estimates of HRs in the study population of
valid reporters of energy intake did also not reach the level of
statistical significance (HR per two unit increments in arMED¼ 0.95;
95% CI: 0.88–1.03). Furthermore, no differences in risk estimates
were seen after removing each arMED component of the score
(Table 3). In addition, none of these components was individually
associated with pancreatic cancer risk in multivariate-adjusted
models controlling for the remaining components (data not shown).
DISCUSSION
Risk of pancreatic cancer was not associated with adherence to a
non-alcohol defined MD score (arMED) in this large European
prospective cohort study, nor was there any evidence of a
significant association between the arMED score and pancreatic
cancer risk in stratified analyses by diabetes, smoking, BMI or
European region.
Few studies have examined the association between adherence
to the MD and pancreatic cancer risk. The National Institutes of
Health-AARP Diet and Health Study prospectively evaluated this
association in a diabetes-free study population including 1057
pancreatic cancer cases (Jiao et al, 2009). In this study, adherence
to the MD was considered as part of a healthy lifestyle score, which
also included tobacco and alcohol consumption, BMI and physical
activity. The MD score was derived from the MDS (Trichopoulou
et al, 2003), but was further adapted by removing the alcohol
component. The risk of pancreatic cancer was significantly lower in
participants who scored highest compared with those in the group
of lowest compliance with the lifestyle score (RR¼ 0.42; 95% CI:
0.26–0.66). The independent effect of the MD score on pancreatic
cancer risk was also evaluated in this study, but a non-statistically
significant 8% (95% CI 0.81–1.05) reduced pancreatic cancer risk
was seen when a high vs a low non-alcohol MD adherence was
compared, indicating that a healthy dietary pattern, such as the
MD, may not have the capacity on its own to reduce risk of
pancreatic cancer. Interestingly, non-smoking (never or former
smokers who quit smoking for 10 or more years) and normal
Table 2. ( Continued )
arMED score Per two unit increment in arMED score
Low (0–5) HR
(95% CI)
Medium (6–9) HR
(95% CI)
High (10–16) HR
(95% CI)
P-value for trend HR (95% CI)
Moderate drinkers (n¼437 cases)a
Cases/person-years 120/697 692 123/1 422 417 104/836 632
Crude HR (95% CI) 1.00 1.08 (0.85–1.37) 1.13 (0.81–1.58) 0.46 1.03 (0.94–1.12)
Multivariate HR (95% CI) 1.00 1.12 (0.88–1.43) 1.20 (0.86–1.69) 0.27 1.05 (0.96–1.15)
Drinkers (n¼319 cases)a
Cases/person-years 123/419 807 144/760 477 52/419 578
Crude HR (95% CI) 1.00 0.85 (0.66–1.11) 0.73 (0.48–1.11) 0.12 0.90 (0.81–1.00)
Multivariate HR (95% CI) 1.00 0.95 (0.73–1.24) 0.84 (0.55–1.29) 0.45 0.95 (0.85–1.05)
Abdominal obese (n¼237 cases)b P-value for interaction: 0.76
Cases/person-years 69/226 129 106/373 247 62/328 889
Crude HR (95% CI) 1.00 1.20 (0.87–1.67) 0.87 (0.53–1.44) 0.84 0.96 (0.85–1.09)
Multivariate HR (95% CI) 1.00 1.29 (0.92–1.80) 0.98 (0.59–1.62) 0.80 0.99 (0.87–1.12)
Normal/moderate WC (n¼522 cases)b
Cases/person-years 172/727 819 247/1 465 094 103/990 891
Crude HR (95% CI) 1.00 0.90 (0.74–1.11) 0.82 (0.60–1.12) 0.20 0.97 (0.89–1.05)
Multivariate HR (95% CI) 1.00 0.97 (0.79–1.20) 0.94 (0.68–1.28) 0.68 1.01 (0.93–1.09)
Southern Europe (n¼163 cases)c P-value for interaction: 0.11
Cases/person-years 2/22 293 67/434 389 94/774 018
Crude HR (95% CI) 1.00 1.57 (0.38–6.48) 1.07 (0.26–4.45) 0.06 0.86 (0.74–1.00)
Multivariate HR (95% CI) 1.00 1.60 (0.39–6.61) 1.16 (0.28–4.81) 0.12 0.88 (0.76–1.03)
Central Europe (n¼341 cases)c
Cases/person-years 93/577 960 179/1 255 044 69/616 619
Crude HR (95% CI) 1.00 1.06 (0.82–1.38) 1.25 (0.87–1.80) 0.25 1.04 (0.94–1.15)
Multivariate HR (95% CI) 1.00 1.10 (0.85–1.44) 1.33 (0.92–1.93) 0.14 1.06 (0.96–1.17)
Northern Europe (n¼361 cases)c
Cases/person-years 182/644 942 156/794 302 23/143 430
Crude HR (95% CI) 1.00 0.83 (0.67–1.04) 0.79 (0.50–1.23) 0.10 0.94 (0.85–1.03)
Multivariate HR (95% CI) 1.00 0.92 (0.73–1.15) 0.93 (0.59–1.47) 0.52 0.99 (0.90–1.09)
Crude HRs—stratified by age (1-year categories), sex and centre. Multivariate HRs—adjusted for total energy intake (continuous), body mass index (continuous), smoking status and intensity
(never; current, 1–15 cigarettes per day; current, 16–25 cigarettes per day; current, 26þ cigarettes per day; former, quit p10 years; former, quit 11–20 years; former, quit 20þ years; current,
pipe/cigar/occasional; current/former, missing; unknown), alcohol intake (non-drinkers, drinkers of 0–6g per day, 46–12g per day, 412–24g per day, 424–60g per day, women drinkers of:
460g per day, men drinkers of:460–96g per day, 496g per day), diabetes (verified, not verified but self-reported, not diabetes, missing), and stratified by age (1-year categories), sex and
centre. Abdominal obesity, according to NCEP/ATPIII criteria, was defined as waist circumference X102 cm in men or X88 cm in women, and normal and moderate waist circumference as
o120 cm or o88 cm in men and women, respectively. Multivariate HRs additionally controlling for BMI retrieved similar estimates.
aNon-drinkers: 0 drinks per day (0 g per day alcohol); moderate drinkers: no more than 1 drink/d (4=12g per day alcohol); drinkers: more than 1 drink per day (412g per day alcohol).
bObese, overweight and normal weight was defined according to WHO criteria, as X30 kg m2, 25–30 kg m2 and p25 kg m2, respectively.
cSouthern Europe: Spain, Italy and Greece; Central Europe: France, Germany, UK and The Netherlands; Northern Europe: Sweden, Denmark and Norway.
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weight (BMIo25 kgm2) were the only two features of the lifestyle
score independently associated with a decreased pancreatic cancer
risk. Non-smoking yielded the greatest risk reduction within the
score (RR¼ non-smokers vs smokers¼ 0.59; 95% CI: 0.51–0.67).
Therefore, the pancreatic cancer risk-reducing effect of this lifestyle
score could be entirely attributed to the smoking component. In
support of this argument, a cross-comparison of smoking status
and levels of adherence to the arMED score in our study revealed
that non-smokers, defined likewise as never or long-term former
smokers (X10 years), with a high adherence to the arMED score as
compared with current smokers or early former smokers with a
low adherence to the arMED score had a 42% (95% CI: 0.43–0.78)
lower risk of pancreatic cancer.
Another prospective study addressing the association between
adherence to the MD (defined as the MDS, with some modifications)
and pancreatic cancer mortality reported a 28% reduction in mortality
(though, statistically significant only in men: 95% CI: 0.68–0.99) for
high vs low adherence to the MD score (Tognon et al, 2012). This study
included only 92 pancreatic cancer cases, which were ascertained in
Sweden among the 77151 participants of the Va¨sterbotten Intervention
Program study. Residual confounding and selection bias (subjects with
higher mortality risk were excluded) prevent direct comparison of their
results with those obtained in our study. The only study reporting a
significant association between the MD (the MDS) and pancreatic
cancer is an Italian case–control study that included 688 cases and
2204 hospital-based controls. In this study, risk of pancreatic cancer
decreased by 15% (95% CI: 0.80–0.91) per one unit increment in the
adherence to the MD (Bosetti et al, 2013a, b). This association was
consistent across strata of age, BMI, alcohol and smoking status, and
was stronger in non-diabetics (OR¼ 0.84) as compared with diabetics
(OR¼ 0.99; P-value for interaction: 0.01). In our study, high vs low
adherence to the arMED score also pointed to a stronger, though non-
statistically significant, inverse association between the MD and
pancreatic cancer risk in non-diabetics (HR¼ 0.91; 95% CI: 0.70–
1.19). We could not examine the association in diabetics because only
55 of them developed pancreatic cancer during follow-up, but we did
not observe any evidence for effect modification by diabetes status. The
other prospective studies did not assess how MD is associated with
pancreatic cancer risk in diabetics as compared with non-diabetics.
Although the number of diabetics with pancreatic cancer was limited in
number in our study population, our results suggest that diabetes status
does not mediate any possible association between the MD and
pancreatic cancer risk.
Finally, a recently published meta-analysis on the adherence to the
MD and cancer incidence and mortality concluded for pancreatic
cancer that a high adherence to this dietary pattern leads to a statis-
tically non-significant reduced risk (RR¼ 0.64; 95% CI: 0.38–1.08)
when compared with a low adherence (Schwingshackl and Hoffmann,
2014). However, this reported risk estimate was not derived from all
available published studies on this association; only estimates of the
Italian and Swedish studies were pooled.
All of these earlier studies exploring the association between
the MD and pancreatic cancer risk are prone to misclassification of
the outcome (data for histologically confirmed cases were not
provided), and some of them did not account for implausible
reporting of dietary intake on the basis of estimated energy
requirements to rule out exposure misclassification. Selection bias,
although less likely present in cohort studies, might be another
issue. Also, MD patterns in American and Nordic populations
might not adequately reflect the traditional MD pattern. In our
study, the association was, indeed, to some extent stronger in
southern European countries, though it still did not reach statistical
significance. Thus, our results seem to indicate that adherence to
the MD does not reduce pancreatic cancer risk.
Similarly, two prospective studies assessing a posteriori-defined
MD-like dietary patterns reported no association with pancreatic
cancer risk (Michaud et al, 2005; Inoue-Choi et al, 2011). Also,
neither single dietary components of the MD nor the combination
of them in the arMED score appeared to be linked to pancreatic
cancer risk in our study. In addition, we rendered similar risk
estimates after considering the traditional rMED score that
includes the alcohol component (Buckland et al, 2010). Overall,
evidence supporting a role of dietary factors commonly supplied by
the MD (antioxidant-rich foods, such as fruits and vegetables, and
limited intake of red meat) for the prevention of this disease is still
sparse (Vrieling et al, 2009; AICR/WCRF, 2012; Koushik et al,
2012; Larsson and Wolk, 2012; Rohrmann et al, 2013).
Several limitations of this study should be considered. Our results
rely on dietary data measured at a single time point, which would not
reflect longitudinal changes in dietary intake. Residual confounding
might be present as we were unable to control for all known risk
factors of pancreatic cancer, such as family history of pancreatic
Table 3. Hazard ratios and 95% CIs of pancreatic cancer associated with the arMED score in the EPIC cohort (n¼477309) after
removing score components one at a time
HRa (95% CI)
arMED
component
(g per day)
Mean±s.d.
Low (0–5) HR
(95% CI)
Medium (6–9) HR
(95% CI)
High (10–16) HR
(95% CI)
P-value for trend
Per two unit increment
in arMED score HR
(95% CI)
Vegetablesb 106.7±74.3 1.00 0.98 (0.84–1.15) 0.94 (0.71–1.26) 0.72 0.99 (0.92–1.06)
Fruitsb 120.2±90.5 1.00 1.03 (0.88–1.21) 1.02 (0.77–1.35) 0.79 1.00 (0.93–1.07)
Legumesb 7.1±11.0 1.00 1.05 (0.90–1.23) 1.02 (0.78–1.34) 0.69 1.00 (0.94–1.07)
Fishb 18.9±19.1 1.00 1.04 (0.88–1.23) 1.04 (0.78–1.37) 0.69 0.99 (0.96–1.03)
Cerealsb 161.5±110.8 1.00 0.98 (0.83–1.15) 0.89 (0.67–1.18) 0.50 1.00 (0.94–1.08)
Olive oilb 3.3±6.7 1.00 0.91 (0.78–1.06) 1.00 (0.77–1.30) 0.62 0.99 (0.93–1.06)
Meatb 47.4±25.0 1.00 1.02 (0.86–1.20) 1.08 (0.82–1.42) 0.64 1.00 (0.94–1.08)
Diary productsb 161.5±110.8 1.00 1.04 (0.88–1.23) 1.09 (0.83–1.44) 0.51 1.01 (0.94–1.08)
Alcoholc 0.4±0.5 1.00 1.01 (0.85–1.19) 0.99 (0.77–1.26) 0.95 1.00 (0.94–1.06)
Intakes adjusted by energy intake (1000 kcal). Multivariate HRs did not include alcohol intake.
aMultivariate HRs—adjusted for total energy intake (continuous), body mass index (continuous), smoking status and intensity (never; current, 1–15 cigarettes per day; current, 16–25 cigarettes
per day; current, 26þ cigarettes per day; former, quit p10 years; former, quit 11–20 years; former, quit 20þ years; current, pipe/cigar/occasional; current/former, missing; unknown), alcohol
intake (non-drinkers, drinkers of 0–6g per day,46–12g per day,412–24g per day,424–60g per day, women drinkers of:460g per day, men drinkers of:460–96 g per day,496g per day),
diabetes (verified, not verified but self-reported, not diabetes, missing) and stratified by age (1-year categories), sex and centre.
bReferers to the arMED score. Adherence score is based on 14 points.
cRefers to the rMED score. Adherence score is based on 16 points.
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cancer, or for other putative factors potentially associated with
pancreatic cancer risk. Confounding by smoking might be also an
issue, despite the fact that additionally controlling for smoking
duration and intensity did not substantially affect our results. Diabetes
mellitus status could have biased our results due to misclassification,
but neither self-reported nor validated data on type 2 diabetes mellitus
status at baseline made a substantial difference.
Strengths of our study are its prospective nature, as well as the large
sample size and long follow-up, which enabled us to conduct stratified
analysis by potential effect modifiers with sufficient statistical power.
Also, we were able to minimise bias due to misclassification of the
outcome after restricting the study population to microscopically
confirmed cases, and could confirm absence of any influence of
pre-diagnostic disease on the association. Moreover, our results
remained unchanged at different follow-up time points. We excluded
misreporters of energy intake to ensure that reporting bias did not
influence our results. However, as in any other diet-cancer association
study, dietary measurement error cannot be dismissed. Our results
also rely on a MD score that has been widely used in diet-cancer risk-
association studies, in which the utility of the MD for the primary
prevention of various cancer sites was demonstrated (Buckland et al,
2010, 2013; Bamia et al, 2013). Moreover, our study addresses
the MD-pancreatic cancer risk association, for the first time, in a
large European population that includes countries from the Medi-
terranean regions, accounting for a wide range of adherence to the
MD pattern.
In conclusion, results of our study, conducted within the
prospective EPIC cohort, suggest that adherence to the MD is not
associated with the development of pancreatic cancer.
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